Health Policy
Function
The Working Group on Health Policy deals with business and political parameters, ranging from licensing, paths to reimbursement, market access and care to billing for biopharmaceutical products. More broadly, its work also involves analysing the business policy and health economy policy issues of the legal parameters for Germany as a biotech location.
Co-ordinators
Prof. Dr. Helga Rübsamen-Schaeff
AiCuris Anti-infective Cures GmbH
Prof. Dr. med. Niels Riedemann
InflaRx GmbH
Experts from the following companies
- AbbVie Deutschland GmbH & Co. KG
- Accessus Health GmbH
- AiCuris Anti-infective Cures AG
- Atriva Therapeutics GmbH
- Bayer AG
- Bayerische Patentallianz GmbH
- Berliner Institut für Gesundheitsforschung (BIH)
- Berlin Partner für Wirtschaft und Technologie GmbH
- BIOCOM AG
- BioNTech SE
- D+B Rechtsanwälte Partnerschaft mbH
- EUCOPE - European Confederation of Pharmaceutical Entrepreneurs AISBL
- FGK Clinical Research GmbH
- Guardant Health
- InflaRx GmbH
- ITF Pharma GmbH
- ITM Medical Isotopes GmbH
- Jones Day
- Menarini Stemline Deutschland GmbH
- Miltenyi Biotec B.V. & Co. KG
- NDA Regulatory Service GmbH
- Novartis Pharma Oncology GmbH
- Osborne Clarke
- Oxford Nanopore Technologies Ltd.
- Pfizer Deutschland GmbH
- Pharmalex GmbH
- Sanofi-Aventis Deutschland GmbH
- Serum Life Sciences Europe GmbH
- Sinfonie Life Science Management GmbH
- Synovo GmbH
- Thermo Fisher Scientific
- TME Pharma AG
- Vintura GmbH